Posted inInfectious Diseases news Pediatrics
Clesrovimab for Prolonged Protection Against Severe RSV in High-Risk Infants: Insights From a Two-Season Randomized Trial
This phase 3 trial demonstrates that clesrovimab, a long-acting monoclonal antibody, is safe and well-tolerated in infants at risk for severe RSV disease across two consecutive RSV seasons, supporting its role in extended RSV prophylaxis.